Psilocybin for depression in amyotrophic lateral sclerosis
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether psilocybin, a psychedelic drug, can safely help with depression in people with ALS. It also looks at how the drug affects your symptoms and quality of life over six months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of ALS that is possible, probable, or definite.
- Your breathing strength is above a certain level (more than 50% of expected).
- You can swallow tablets by mouth (a feeding tube is okay, but you must take the pill by mouth).
- You have significant symptoms of depression, as shown by a score above 22 on a special depression scale.
- You are not taking certain antidepressants or other medications that could interact with psilocybin, and you are not on a breathing machine (tracheostomy, CPAP, or BiPAP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.
This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.
This trial tests whether psilocybin (a substance found in certain mushrooms) can help treat depression in people with a spinal cord injury. You would receive the study drug in a controlled setting, and your progress would be monitored closely.
This study tests whether psilocybin (a naturally occurring psychedelic compound) combined with therapy can help treat depression. Researchers will give you a single dose of psilocybin in a controlled medical setting while providing psychological support to see if it reduces your depression symptoms.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.